| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | 1H-Benzimidazole, 2-[2-(2-furanyl)ethenyl]-1-(2-propen-1-yl)-, hydrochloride (1:1) Basic information |
| | 1H-Benzimidazole, 2-[2-(2-furanyl)ethenyl]-1-(2-propen-1-yl)-, hydrochloride (1:1) Chemical Properties |
| | 1H-Benzimidazole, 2-[2-(2-furanyl)ethenyl]-1-(2-propen-1-yl)-, hydrochloride (1:1) Usage And Synthesis |
| Uses | CDKI-IN-1 (Compound SNX12) is a cyclin-dependent kinase inhibitor (CDKI) inhibitor that can be used for research into degenerative diseases of the central nervous system[1]. | | References | [1] Bey-Dih Chang, et al. Cdki pathway inhibitors and uses thereof. Patent, US20090281129. 2009-11-12. |
| | 1H-Benzimidazole, 2-[2-(2-furanyl)ethenyl]-1-(2-propen-1-yl)-, hydrochloride (1:1) Preparation Products And Raw materials |
|